C4 Therapeutics, Inc (CCCC)

$7.38

+0.89

(+13.71%)

Market is closed - opens 7 PM, 17 Jul 2024

Performance

  • $6.61
    $7.66
    $7.38
    downward going graph

    10.43%

    Downside

    Day's Volatility :13.65%

    Upside

    3.59%

    downward going graph
  • $1.06
    $11.88
    $7.38
    downward going graph

    85.64%

    Downside

    52 Weeks Volatility :91.08%

    Upside

    37.88%

    downward going graph

Returns

PeriodC4 Therapeutics, IncSector (Health Care)Index (Russel 2000)
3 Months
7.42%
8.2%
0.0%
6 Months
11.99%
7.5%
0.0%
1 Year
114.53%
14.3%
0.0%
3 Years
-81.31%
16.5%
-18.2%

Highlights

Market Capitalization
507.8M
Book Value
$3.76
Earnings Per Share (EPS)
-2.37
Wall Street Target Price
18.86
Profit Margin
0.0%
Operating Margin TTM
-979.99%
Return On Assets TTM
-20.86%
Return On Equity TTM
-48.42%
Revenue TTM
20.0M
Revenue Per Share TTM
0.37
Quarterly Revenue Growth YOY
-19.2%
Gross Profit TTM
-86.7M
EBITDA
-130.8M
Diluted Eps TTM
-2.37
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.54
EPS Estimate Next Year
-1.82
EPS Estimate Current Quarter
-0.35
EPS Estimate Next Quarter
-0.5

Analyst Recommendation

Buy
    73%Buy
    26%Hold
    0
    0%Sell
Based on 15 Wall street analysts offering stock ratings for C4 Therapeutics, Inc(by analysts ranked 0 to 5 stars)
Based on 15 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
11
11
13
Hold
4
4
4
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 155.56%

Current $7.38
Target $18.86

Company Financials

FY18Y/Y Change
Revenue
19.4M
-
Net Income
-15.7M
-
Net Profit Margin
-81.14%
-
FY19Y/Y Change
Revenue
21.4M
↑ 10.42%
Net Income
-34.1M
↑ 117.04%
Net Profit Margin
-159.48%
↓ 78.34%
FY20Y/Y Change
Revenue
33.2M
↑ 55.25%
Net Income
-66.3M
↑ 94.54%
Net Profit Margin
-199.83%
↓ 40.35%
FY21Y/Y Change
Revenue
45.8M
↑ 37.93%
Net Income
-86.0M
↑ 29.7%
Net Profit Margin
-187.92%
↑ 11.91%
FY22Y/Y Change
Revenue
31.1M
↓ 32.08%
Net Income
-126.5M
↑ 47.03%
Net Profit Margin
-406.8%
↓ 218.88%
FY23Y/Y Change
Revenue
20.8M
↓ 33.25%
Net Income
-132.5M
↑ 4.74%
Net Profit Margin
-638.34%
↓ 231.54%
Q4 FY22Q/Q Change
Revenue
2.9M
↓ 57.74%
Net Income
-36.1M
↑ 14.79%
Net Profit Margin
-1.3K%
↓ 798.77%
Q1 FY23Q/Q Change
Revenue
3.8M
↑ 31.71%
Net Income
-33.9M
↓ 5.93%
Net Profit Margin
-902.85%
↑ 361.24%
Q2 FY23Q/Q Change
Revenue
2.7M
↓ 29.13%
Net Income
-35.9M
↑ 5.85%
Net Profit Margin
-1.3K%
↓ 445.57%
Q3 FY23Q/Q Change
Revenue
11.1M
↑ 315.62%
Net Income
-27.0M
↓ 24.73%
Net Profit Margin
-244.19%
↑ 1104.23%
Q4 FY23Q/Q Change
Revenue
3.3M
↓ 70.55%
Net Income
-34.8M
↑ 28.54%
Net Profit Margin
-1.1K%
↓ 821.56%
Q1 FY24Q/Q Change
Revenue
3.0M
↓ 6.81%
Net Income
-28.4M
↓ 18.4%
Net Profit Margin
-933.23%
↑ 132.52%
FY18Y/Y Change
Total Assets
146.5M
-
Total Liabilities
226.2M
-
FY19Y/Y Change
Total Assets
118.3M
↓ 19.27%
Total Liabilities
230.2M
↑ 1.76%
FY20Y/Y Change
Total Assets
400.1M
↑ 238.35%
Total Liabilities
119.3M
↓ 48.16%
FY21Y/Y Change
Total Assets
506.8M
↑ 26.65%
Total Liabilities
117.2M
↓ 1.83%
FY22Y/Y Change
Total Assets
430.8M
↓ 14.98%
Total Liabilities
141.6M
↑ 20.87%
FY23Y/Y Change
Total Assets
376.5M
↓ 12.62%
Total Liabilities
130.3M
↓ 7.96%
Q4 FY22Q/Q Change
Total Assets
430.8M
↓ 6.63%
Total Liabilities
141.6M
↓ 1.15%
Q1 FY23Q/Q Change
Total Assets
396.0M
↓ 8.08%
Total Liabilities
133.6M
↓ 5.68%
Q2 FY23Q/Q Change
Total Assets
375.0M
↓ 5.31%
Total Liabilities
141.3M
↑ 5.79%
Q3 FY23Q/Q Change
Total Assets
333.0M
↓ 11.2%
Total Liabilities
117.0M
↓ 17.21%
Q4 FY23Q/Q Change
Total Assets
376.5M
↑ 13.04%
Total Liabilities
130.3M
↑ 11.41%
Q1 FY24Q/Q Change
Total Assets
398.4M
↑ 5.82%
Total Liabilities
140.1M
↑ 7.48%
FY18Y/Y Change
Operating Cash Flow
-17.0M
-
Investing Cash Flow
36.9M
-
Financing Cash Flow
2.0M
-
FY19Y/Y Change
Operating Cash Flow
55.6M
↓ 427.51%
Investing Cash Flow
-1.6M
↓ 104.39%
Financing Cash Flow
244.0K
↓ 87.56%
FY20Y/Y Change
Operating Cash Flow
-67.2M
↓ 220.92%
Investing Cash Flow
-190.5M
↑ 11659.57%
Financing Cash Flow
348.9M
↑ 142904.92%
FY21Y/Y Change
Operating Cash Flow
-87.0M
↑ 29.32%
Investing Cash Flow
-189.3M
↓ 0.61%
Financing Cash Flow
171.4M
↓ 50.88%
FY22Y/Y Change
Operating Cash Flow
-105.9M
↑ 21.82%
Investing Cash Flow
58.4M
↓ 130.86%
Financing Cash Flow
1.1M
↓ 99.33%
Q4 FY22Q/Q Change
Operating Cash Flow
-29.1M
↑ 3.95%
Investing Cash Flow
9.3M
↓ 53.38%
Financing Cash Flow
47.0K
↓ 86.98%
Q1 FY23Q/Q Change
Operating Cash Flow
-33.1M
↑ 13.72%
Investing Cash Flow
15.1M
↑ 63.16%
Financing Cash Flow
-684.0K
↓ 1555.32%
Q2 FY23Q/Q Change
Operating Cash Flow
-19.0M
↓ 42.65%
Investing Cash Flow
15.1M
↑ 0.0%
Financing Cash Flow
-746.0K
↑ 9.06%

Technicals Summary

Sell

Neutral

Buy

C4 Therapeutics, Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
C4 Therapeutics, Inc
C4 Therapeutics, Inc
78.26%
11.99%
114.53%
-81.31%
-71.05%
Moderna, Inc.
Moderna, Inc.
-9.25%
24.7%
2.07%
-60.09%
791.95%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
4.75%
17.85%
51.74%
87.1%
265.7%
Novo Nordisk A/s
Novo Nordisk A/s
0.36%
32.05%
75.05%
218.96%
483.19%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
3.23%
12.73%
36.59%
145.42%
176.04%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
C4 Therapeutics, Inc
C4 Therapeutics, Inc
NA
NA
NA
-1.54
-0.48
-0.21
NA
3.76
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.18
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
31.94
31.94
1.46
44.22
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
48.76
48.76
2.36
3.45
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
31.85
31.85
0.53
17.07
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
C4 Therapeutics, Inc
C4 Therapeutics, Inc
Buy
$507.8M
-71.05%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$48.0B
791.95%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$119.2B
265.7%
31.94
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$633.1B
483.19%
48.76
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$126.7B
176.04%
31.85
39.46%

Insights on C4 Therapeutics, Inc

  • Decreasing Revenue

    Revenue is down for the last 3 quarters, 11.07M → 3.03M (in $), with an average decrease of 38.7% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -34.75M → -28.36M (in $), with an average increase of 22.5% per quarter

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 217.8% return, outperforming this stock by 299.3%

Institutional Holdings

  • State Street Corporation

    10.40%
  • RA Capital Management, LLC

    7.09%
  • Wasatch Advisors LP

    6.29%
  • COMMODORE CAPITAL LP

    4.96%
  • Vanguard Group Inc

    4.24%
  • Soleus Capital Management, L.P.

    3.57%

Company Information

c4 therapeutics is an early stage drug discovery company whose mission is to harness targeted protein degradation to develop therapeutics for a broad range of diseases. the centerpiece of our approach is the degronimid® platform, which enables highly selective small molecule binders to target disease causing proteins and facilitate their rapid destruction and clearance from the cell through the natural ubiquitin/proteasome system.

Organization
C4 Therapeutics, Inc
Employees
145
CEO
Mr. Andrew J. Hirsch M.B.A.
Industry
Health Technology

FAQs